Evidence map›Paper›PMID 34754035›Full record

ArticleScientific reports2021

Gene-corrected p.A30P SNCA patient-derived isogenic neurons rescue neuronal branching and function.

Peter A Barbuti, Jochen Ohnmacht, Bruno F R Santos, Paul M Antony, François Massart, Gérald Cruciani, Claire M Dording, Lukas Pavelka, Nicolas Casadei, Yong-Jun Kwon and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. α-Synuclein Pathology and Reduced Neurogenesis in the Olfactory System Affect Olfaction in a Mouse Model of Parkinson's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Peter A BarbutiTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg. pab2184@cumc.columbia.edu.
Jochen Ohnmacht *Translational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Bruno F R Santos *Translational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Paul M AntonyTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
François MassartTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Gérald CrucianiTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Claire M DordingTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Lukas PavelkaTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg.
Nicolas CasadeiInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Yong-Jun KwonDisease Modeling and Screening Platform (DMSP), Luxembourg Centre for Systems Biomedicine, University of Luxembourg & Luxembourg Institute of Health, 6 avenue du Swing, 4367, Belvaux, Luxembourg.
Rejko KrügerTranslational Neuroscience, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, 4362, Esch-sur-Alzette, Luxembourg. rejko.kruger@lih.lu.
Luxembourg Institute of Health · LUUniversity of Luxembourg · LUUniversity of Tübingen · DE

Funding

Deutsche Forschungsgemeinschaft INST 37/1049-1Fonds National de la Recherche Luxembourg FNR/P13/6682797Fonds National de la Recherche Luxembourg INTER/LEIR/18/12719318Horizon 2020 Framework Programme 692320
6 · The paper itself

Abstract

Parkinson's disease (PD) is characterised by the degeneration of A9 dopaminergic neurons and the pathological accumulation of alpha-synuclein. The p.A30P SNCA mutation generates the pathogenic form of the alpha-synuclein protein causing an autosomal-dominant form of PD. There are limited studies assessing pathogenic SNCA mutations in patient-derived isogenic cell models. Here we provide a functional assessment of dopaminergic neurons derived from a patient harbouring the p.A30P SNCA mutation. Using two clonal gene-corrected isogenic cell lines we identified image-based phenotypes showing impaired neuritic processes. The pathological neurons displayed impaired neuronal activity, reduced mitochondrial respiration, an energy deficit, vulnerability to rotenone, and transcriptional alterations in lipid metabolism. Our data describes for the first time the mutation-only effect of the p.A30P SNCA mutation on neuronal function, supporting the use of isogenic cell lines in identifying image-based pathological phenotypes that can serve as an entry point for future disease-modifying compound screenings and drug discovery strategies.

Indexed as

Mutationalpha-SynucleinCell LineDopaminergic NeuronsHumansMitochondriaParkinson Diseasealpha-SynucleinSNCA protein, human

Identifiers

PMID34754035
PMCPMC8578337
OpenAlexW3214319747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.